positive
Novo Nordisk to Acquire Akero Therapeutics in Up to $5.2B Deal; SoftBank-ABB Robotics Sale Boosts Nikkei
Danish pharma giant Novo Nordisk announced a potential acquisition of US biotech firm Akero Therapeutics for up to $5.2 billion, pending federal approval of Akero's lead product candidate, sending Akero shares up over 16%. In global markets, Japan's Nikkei 225 surged, led by SoftBank Group shares rising 11.4% after a $5.4 billion deal to acquire ABB's robotics unit. Meanwhile, the ongoing US government shutdown delays key economic data, keeping investors focused on corporate earnings and Federal Reserve speeches for market direction.
Companies:
- Oyo
Tags:
- Mergers and Acquisitions (M&A)
- Pharmaceuticals
positive
Novo Nordisk to Acquire Akero Therapeutics in Up to $5.2B Deal; SoftBank-ABB Robotics Sale Boosts Nikkei
Danish pharma giant Novo Nordisk announced a potential acquisition of US biotech firm Akero Therapeutics for up to $5.2 billion, pending federal approval of Akero's lead product candidate, sending Akero shares up over 16%. In global markets, Japan's Nikkei 225 surged, led by SoftBank Group shares rising 11.4% after a $5.4 billion deal to acquire ABB's robotics unit. Meanwhile, the ongoing US government shutdown delays key economic data, keeping investors focused on corporate earnings and Federal Reserve speeches for market direction.
Companies:
- Oyo
Tags:
- Mergers and Acquisitions (M&A)
- Pharmaceuticals
1 min read
81 words
Novo Nordisk to acquire Akero Therapeutics for up to $5.2B, pending drug approval. SoftBank jumps 11.4% on $5.4B ABB robotics deal.
Danish pharma giant Novo Nordisk announced a potential acquisition of US biotech firm Akero Therapeutics for up to $5.2 billion, pending federal approval of Akero's lead product candidate, sending Akero shares up over 16%. In global markets, Japan's Nikkei 225 surged, led by SoftBank Group shares rising 11.4% after a $5.4 billion deal to acquire ABB's robotics unit. Meanwhile, the ongoing US government shutdown delays key economic data, keeping investors focused on corporate earnings and Federal Reserve speeches for market direction.
Danish pharma giant Novo Nordisk announced a potential acquisition of US biotech firm Akero Therapeutics for up to $5.2 billion, pending federal approval of Akero's lead product candidate, sending Akero shares up over 16%. In global markets, Japan's Nikkei 225 surged, led by SoftBank Group shares rising 11.4% after a $5.4 billion deal to acquire ABB's robotics unit. Meanwhile, the ongoing US government shutdown delays key economic data, keeping investors focused on corporate earnings and Federal Reserve speeches for market direction.
Companies:
- Oyo
Tags:
- Mergers and Acquisitions (M&A)
- Pharmaceuticals
- Mergers and Acquisitions (M&A)
- Pharmaceuticals
- Biotech
- Robotics
- Nikkei
- Global Markets
- Novo Nordisk
- SoftBank